Complement-mediated enhancement of SARS-CoV-2 antibody neutralisation potency in vaccinated individuals.
Mellors J. et al, (2025), Nature communications, 16
Time to HIV viral rebound and frequency of post-treatment control after analytical interruption of antiretroviral therapy: an individual data-based meta-analysis of 24 prospective studies
Gunst JD. et al, (2025), Nature Communications, 16
MHC-related protein 1-restricted recognition of cancer via a semi-invariant TCR-α chain.
Dolton G. et al, (2025), The Journal of clinical investigation, 135
Learning patterns of HIV-1 resistance to broadly neutralizing antibodies with reduced subtype bias using multi-task learning
Igiraneza AB. et al, (2024), PLOS Computational Biology, 20, e1012618 - e1012618
Footprints of innate immune activity during HIV-1 reservoir cell evolution in early-treated infection
Sun W. et al, (2024), Journal of Experimental Medicine, 221
Obesity differs from diabetes mellitus in antibody and T-cell responses post-COVID-19 recovery
Ali M. et al, (2024), Clinical and Experimental Immunology, 218, 78 - 92
Impact of antiretroviral therapy during primary HIV infection on T‐cell immunity after treatment interruption
Tipoe T. et al, (2024), European Journal of Immunology
Prevalence of resistance-associated viral variants to the HIV-specific broadly neutralising antibody 10-1074 in a UK bNAb-naïve population
Zacharopoulou P. et al, (2024), Frontiers in Immunology, 15
Enhancing broadly neutralising antibody suppression of HIV by immune modulation and vaccination.
Nel C. and Frater J., (2024), Frontiers in immunology, 15
Rapid antiretroviral therapy in primary HIV-1 infection enhances immune recovery.
Thornhill JP. et al, (2023), AIDS (London, England)
Therapeutic vaccination following early antiretroviral therapy elicits highly functional T cell responses against conserved HIV-1 regions.
Kopycinski J. et al, (2023), Sci Rep, 13
SARS-CoV-2-specific immune responses and clinical outcomes after COVID-19 vaccination in patients with immune-suppressive disease
Barnes E. et al, (2023), Nature Medicine, 29, 1760 - 1774
The impact of pre-existing cross-reactive immunity on SARS-CoV-2 infection and vaccine responses
Murray SM. et al, (2023), Nature Reviews Immunology, 23, 304 - 316
Rapid escape of new SARS-CoV-2 Omicron variants from BA.2-directed antibody responses
Dijokaite-Guraliuc A. et al, (2023), Cell Reports, 42, 112271 - 112271
Booster Vaccination Against SARS-CoV-2 Induces Potent Immune Responses in People With Human Immunodeficiency Virus
Fidler S. et al, (2023), Clinical Infectious Diseases, 76, 201 - 209
Analysis of broadly neutralising antibody resistance in adolescents and young people living with HIV
Zacharopoulou P. et al, (2023), HIV MEDICINE, 24, 35 - 35